However, the overall safety profile of taspoglutide was clearly worse than exenatide with respect to gastrointestinal tolerability, systemic allergic reactions, and injection-site reactions.

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

drug in development Taspoglutide Transient nausea Still unknown, drug in development Incretins, including glucagon-like peptide (GLP)-1, are peptide hormones responsible for the 'incretin effect ...